Levofloxacina Farmoz (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing these enzymes from separating DNA strands, the drug halts bacterial cell division and leads to rapid bacterial death, providing a bactericidal effect against many Gram‑positive and Gram‑negative organisms.

The dosage of Levofloxacina Farmoz is determined by the prescribing clinician based on the infection type, severity, patient age, weight, renal function, and other clinical factors. Only a qualified healthcare professional can set the appropriate dose and infusion schedule.

Safety data for levofloxacin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Levofloxacin offers a once‑daily dosing option and a broad spectrum that includes many Gram‑negative and atypical pathogens, similar to moxifloxacin but with a slightly different activity profile against some Gram‑positive organisms. Compared with beta‑lactam antibiotics, levofloxacin provides oral and IV formulations and does not require beta‑lactamase stability, but it carries class‑specific risks such as tendon toxicity.

Levofloxacina Farmoz must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use the product if the temperature has been exceeded or if the solution appears discolored.

The product is given by intravenous infusion. It is typically diluted in a compatible IV fluid and administered over a period defined by the prescriber, often 30‑60 minutes for standard doses. Administration should follow aseptic technique and institutional infusion guidelines.

Serious adverse events include tendon rupture (especially Achilles), QT‑interval prolongation that can precipitate arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored closely for these events, and therapy should be stopped immediately if they occur.

Levofloxacina Farmoz is contraindicated in patients with a known hypersensitivity to levofloxacin or any fluoroquinolone. Caution is advised for individuals with a history of tendon disorders, uncontrolled cardiac arrhythmias, severe renal impairment, or those taking interacting medications such as certain antacids, warfarin, or theophylline. Pregnant or breastfeeding women should only use it when clearly needed.